Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease of the esophagus characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation, whose incidence is rising. It significantly affects patients’ quality of life and, if...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in physiology Vol. 12; p. 815842
Main Authors Racca, Francesca, Pellegatta, Gaia, Cataldo, Giuseppe, Vespa, Edoardo, Carlani, Elisa, Pelaia, Corrado, Paoletti, Giovanni, Messina, Maria Rita, Nappi, Emanuele, Canonica, Giorgio Walter, Repici, Alessandro, Heffler, Enrico
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 12.01.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease of the esophagus characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation, whose incidence is rising. It significantly affects patients’ quality of life and, if left untreated, results in fibrotic complications. Although broad consensus has been achieved on first-line therapy, a subset of patients remains non-responder to standard therapy. The pathogenesis of EoE is multifactorial and results from the complex, still mostly undefined, interaction between genetics and intrinsic factors, environment, and antigenic stimuli. A deep understanding of the pathophysiology of this disease is pivotal for the development of new therapies. This review provides a comprehensive description of the pathophysiology of EoE, starting from major pathogenic mechanisms (genetics, type 2 inflammation, epithelial barrier dysfunction, gastroesophageal reflux, allergens, infections and microbiota) and subsequently focusing on the single protagonists of type 2 inflammation (involved cells, cytokines, soluble effectors, surface proteins and transcription factors) that could represent present and future therapeutic targets, while summarizing previous therapeutic approaches in literature.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Darío Antolín-Amérigo, Ramón y Cajal University Hospital, Spain; Jill Johnson, Aston University, United Kingdom
This article was submitted to Clinical and Translational Physiology, a section of the journal Frontiers in Physiology
Edited by: Gilda Varricchi, University of Naples Federico II, Italy
ISSN:1664-042X
1664-042X
DOI:10.3389/fphys.2021.815842